Hikal Ltd
Hikal Q2 Results 2026 (FY27): Revenue ₹434 Cr, Net loss ₹6 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #44 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Hikal Ltd Q2 FY27 key numbers
- Revenue
- Consolidated Revenue Q2FY27: ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26.
As stated in Hikal Ltd's Q2 FY27 investor presentation · published 3 Nov 2026. Reported figures, not investment advice.
Based on Hikal Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Consolidated Revenue Q2FY27: ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) - Pharmaceuticals Revenue Q2FY27: ₹278 crores, up 47% YoY from ₹190 crores in Q2FY26 (Page 7) - Crop Pr Quarterly EBITDA: ₹45 crores, up 524% YoY (Q2FY27 vs Q2FY26) - EBITDA Margin: 10.3%, up 808 bps YoY - Profit After Tax (PAT): ₹(6) crores, improved 83% YoY (from ₹(35) crores in Q2FY26) - EBITDA margin is 10.3% for Q2FY27 - Margin Outlook: The presentation reiterates full-year guidance of “mid teens growth in Revenue and a substantial improvement in profitability” indicating an expectation of improved margins ahead.
From Hikal Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Hikal's revenue grow in the September 2026 quarter?
2 more points from Hikal Ltd's call on revenue
Create a free account to keep reading this call
What happened to Hikal's margins in Q2 FY27?
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
What capex is Hikal planning?
- Capital expenditure of $60 million invested in new assets (Page 25).
- New Personal Care multipurpose manufacturing facility at Panoli commenced commercial production (Pages 4, 10).
- R&T Centre including Integrated Mini Plant established (Page 22).
- Acquisitions of manufacturing sites: Bangalore site from Wintac Ltd and Panoli site from Novartis (Page 21).
- Co-generation plant and biomass boilers commissioned at all sites as sustainability initiative (Page 21).
2 more points from Hikal Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Hikal raising money or cutting debt?
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Hikal's order book?
Hikal Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Emcure Pharma (Q2 FY27)
Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Key investor presentation takeaways from Emcure Pharmaceuticals Ltd's Q2 FY27 investor pre
- SPARC (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025. Key results state
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Hikal Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hikal Ltd Q2 FY27 results?
Consolidated Revenue Q2FY27: ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) - Pharmaceuticals Revenue Q2FY27: ₹278 crores, up 47% YoY from ₹190 crores in Q2FY26 (Page 7) - Crop Pr Quarterly EBITDA: ₹45 crores, up 524% YoY (Q2FY27 vs Q2FY26) - EBITDA Margin: 10.3%, up 808 bps YoY - Profit After Tax (PAT): ₹(6) crores, improved 83% YoY (from ₹(35) crores in Q2FY26) - EBITDA margin is 10.3% for Q2FY27 - Margin Outlook: The presentation reiterates full-year guidance of “mid teens growth in Revenue and a substantial improvement in profitability” indicating an expectation of improved margins ahead.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 64.2 with a market cap of ₹2,722 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Capital expenditure of $60 million invested in new assets (Page 25).
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.